Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

206.59 +1.68 (+0.82%)

Streaming Delayed Price Updated: 11:48 AM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen ↗

April 01, 2026

Via Chartmill

CLO Sells LGND 5,000 Shares for $1.0 Million ↗

March 30, 2026

Ligand Pharmaceuticals, a leader in drug licensing and royalties, reported a notable insider sale amid strong recent share performance.

Via The Motley Fool

Topics Regulatory Compliance

Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know ↗

March 27, 2026

This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Rice Hall James Buys QuidelOrtho Stock ↗

March 09, 2026

QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings.

Via The Motley Fool

Topics Regulatory Compliance

Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q4 Estimates and Reaffirms 2026 Guidance ↗

February 26, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Rice Hall James Buys Stride Stock ↗

March 09, 2026

Stride delivers online and blended education solutions for K-12, career, and adult learners through proprietary technology platforms.

Via The Motley Fool

Ligand Pharma (LGND) Earnings Call Transcript ↗

February 26, 2026

Ligand Pharma (LGND) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026

February 23, 2026

The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge ↗

February 17, 2026

Vicor Corporation designs advanced power conversion solutions for sectors like aerospace, defense, and industrial automation.

Via The Motley Fool

Sportradar Stock Down 26%, but One Fund Just Disclosed a New $12.6 Million Stake ↗

February 17, 2026

Specializing in sports data and analytics, Sportradar serves betting operators, leagues, and media with real-time technology solutions.

Via The Motley Fool

Topics Regulatory Compliance

What Investors Should Know as One Fund Sells $11 Million of Cavco Industries Stock ↗

February 17, 2026

This Arizona-based firm provides factory-built homes and modular units to residential and commercial clients across North America.

Via The Motley Fool

Topics Regulatory Compliance

Fund Sells $23 Million in Globalstar as Stock Surges 170% in One Year ↗

February 17, 2026

Globalstar delivers satellite communications and IoT connectivity to enterprise and government clients across critical industries worldwide.

Via The Motley Fool

Topics Regulatory Compliance

Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗

February 14, 2026

This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗

February 14, 2026

Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies.

Via The Motley Fool

Topics Energy

Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗

February 14, 2026

Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base.

Via The Motley Fool

Topics Regulatory Compliance

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Via Investor's Business Daily

This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know ↗

November 17, 2025

A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.

Via The Motley Fool

Topics Regulatory Compliance

Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter ↗

November 17, 2025

A specialist small-cap fund just doubled down on a digital-intelligence company that's underperforming the broader market.

Via The Motley Fool

This Fund Cut $7.3 Million of Atlas Energy Stock as the Company Suspends Its Dividend to Help Fuel Growth ↗

November 17, 2025

One fund just took a step back from a struggling energy name—right as the company suspended its dividend to fund future growth.

Via The Motley Fool

Topics Economy Regulatory Compliance

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

November 10, 2025

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch ↗

November 07, 2025

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.

Via Benzinga

Ligand (LGND) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Ligand (LGND) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Ligand Pharmaceuticals (NASDAQ:LGND) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance ↗

November 06, 2025

Ligand (LGND) smashed Q3 2025 earnings estimates, driven by 47% royalty growth. The company also raised its full-year 2025 revenue and EPS guidance.

Via Chartmill

Topics Earnings

What's Next: Ligand Pharmaceuticals's Earnings Preview ↗

November 05, 2025

Via Benzinga

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

What Analysts Are Saying About Ligand Pharmaceuticals Stock ↗

September 02, 2025

Via Benzinga

Ligand (LGND) Q2 Revenue Jumps 15% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth ↗

August 07, 2025

Ligand Pharmaceuticals (LGND) beat Q2 2025 earnings estimates with strong royalty growth, raising full-year guidance. Stock dipped slightly pre-market but gained 16.3% over the past month.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.